Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
äŒæ¥ã³ãŒã- -
äŒç€Ÿå- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°- -
蚌åžçš®é¡- -
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæ- -
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒã- -
äžå Žæ¥- -
æé«çµå¶è²¬ä»»è
ãCEOã- -